UBS Group
EWTX icon

UBS Group’s Edgewise Therapeutics EWTX Stock Holding History

UBS Group’s Portfolio EWTX Stock Details EWTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$41.3M Sell
1,311,125
-805,948
-38% -$23.2M 0.01% 1841
2025
Q4 		$52.5M Buy
2,117,073
+2,002,945
+1,755% +$40.2M 0.01% 1568
2025
Q3 		$1.85M Sell
114,128
-56,854
-33% -$806K ﹤0.01% 5027
2025
Q2 		$2.24M Sell
170,982
-72,914
-30% -$1.05M ﹤0.01% 4694
2025
Q1 		$5.37M Buy
243,896
+151,830
+165% +$3.98M ﹤0.01% 3714
2024
Q4 		$2.46M Buy
92,066
+16,761
+22% +$534K ﹤0.01% 4532
2024
Q3 		$2.01M Buy
75,305
+14,795
+24% +$294K ﹤0.01% 3985
2024
Q2 		$1.09M Sell
60,510
-13,608
-18% -$237K ﹤0.01% 4341
2024
Q1 		$1.35M Buy
+74,118
New +$1.18M ﹤0.01% 4337
2023
Q1 		– Sell
-1,551
Closed -$13.9K – 9795
2022
Q4 		$13.9K Buy
+1,551
New +$14.5K ﹤0.01% 8126
2022
Q2 		– Sell
-22,047
Closed -$214K – 10477
2022
Q1 		$214K Buy
+22,047
New +$284K ﹤0.01% 5298
2021
Q3 		– Sell
-868
Closed -$19K – 9686
2021
Q2 		$19K Buy
+868
New +$23.7K ﹤0.01% 7381

Other funds holding EWTX

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

UBS Group's EWTX Position: Q1 2026 in Review

UBS Group reduced its Edgewise Therapeutics (EWTX) stake by 38% in Q1 2026, selling an estimated $23.2M and leaving 1,311,125 shares worth $41.3M. The position accounts for 0.01% of the portfolio, ranked #1841.

UBS Group first reported a position in EWTX in Q2 2021 and has held it in 12 quarters since. The position peaked at $52.5M in Q4 2025. 214 funds tracked by Wall St. Rank hold EWTX as of Q1 2026.

  • UBS Group held 1,311,125 shares of Edgewise Therapeutics worth $41.3M as of Q1 2026.
  • UBS Group sold 805,948 Edgewise Therapeutics shares in Q1 2026, an estimated $23.2M.
  • Edgewise Therapeutics made up 0.01% of UBS Group's portfolio in Q1 2026, its #1841 holding.
  • UBS Group first reported a position in Edgewise Therapeutics in Q2 2021 and has held it in 12 quarters since.
  • UBS Group's Edgewise Therapeutics position peaked at $52.5M in Q4 2025.
  • 214 funds tracked by Wall St. Rank held Edgewise Therapeutics as of Q1 2026.

Based on UBS Group's 13F filing for Q1 2026, filed 5 May 2026.